Contineum Therapeutics In... (CTNM)
12.89
0.12 (0.94%)
At close: Jan 15, 2025, 3:59 PM
12.96
0.54%
After-hours Jan 15, 2025, 04:00 PM EST
Income Statement (Annual)
Get detailed income statement breakdowns, uncovering revenue, expenses, and much more.
| Year | FY23 | FY22 | FY21 |
| Revenue | 50.00M | n/a | n/a |
| Cost of Revenue | n/a | 329.00K | n/a |
| Gross Profit | 50.00M | -329.00K | n/a |
| Operating Income | 16.08M | -22.72M | -28.65M |
| Interest Income | 4.61M | 761.00K | 77.00K |
| Pretax Income | 23.17M | -24.25M | -29.00M |
| Net Income | 22.72M | -24.25M | -29.00M |
| Selling & General & Admin | 6.32M | 5.50M | 6.29M |
| Research & Development | 27.60M | 16.89M | 22.36M |
| Other Expenses | n/a | -92.00K | -91.00K |
| Operating Expenses | 33.92M | 22.39M | 28.65M |
| Interest Expense | 208.00K | 388.00K | 332.00K |
| Selling & Marketing Expenses | n/a | -329.00K | n/a |
| Cost & Expenses | 33.92M | 22.72M | 28.65M |
| Income Tax | 450.00K | n/a | 241.00K |
| Shares Outstanding (Basic) | 16.67M | 25.13M | 16.67M |
| Shares Outstanding (Diluted) | 17.76M | 25.13M | 17.76M |
| EPS (Basic) | 1.36 | -0.97 | -1.74 |
| EPS (Diluted) | 1.28 | -0.97 | -1.63 |
| EBITDA | 23.57M | -23.54M | -28.34M |
| Depreciation & Amortization | 195.00K | 329.00K | 325.00K |